Literature DB >> 1812956

Plasma protein binding of ketoprofen enantiomers in man: method development and its application.

P J Hayball1, R L Nation, F Bochner, J L Newton, R A Massy-Westropp, D P Hamon.   

Abstract

The protein binding of ketoprofen enantiomers was investigated in human plasma at physiological pH and temperature by ultrafiltration. 14C-labelled (RS)-ketoprofen was synthesized and purified by high-performance liquid chromatography and utilized as a means of quantifying the unbound species. In vitro studies were conducted with plasma obtained from six healthy volunteers. The plasma was spiked with (R)-ketoprofen alone, (S)-ketoprofen alone, and (RS)-ketoprofen in the enantiomeric concentration range of 1.0 to 19.0 micrograms/ml. The plasma protein binding of ketoprofen was nonenantioselective. At a racemic drug concentration of 2.0 micrograms/ml the mean (+/- SD) percentage unbound of (R)-ketoprofen was 0.80 (+/- 0.15)%. The corresponding value for (S)-ketoprofen, 0.78 (+/- 0.18)%, was not statistically different (P greater than 0.05). At this racemic drug concentration (2.0 micrograms/ml) the percentage unbound of each enantiomer was unaffected (P greater than 0.05) by the presence of the glucuronoconjugates of ketoprofen (10 micrograms/ml) in plasma. At clinically relevant concentrations, the plasma binding of ketoprofen did not exhibit enantioselectivity or concentration dependence nor was the binding of either enantiomer influenced by its optical antipode (P greater than 0.05).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1812956     DOI: 10.1002/chir.530030609

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  7 in total

1.  Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study.

Authors:  O Borgå; B Borgå
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

Review 2.  Preclinical and clinical development of dexketoprofen.

Authors:  D Mauleón; R Artigas; M L García; G Carganico
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 3.  Protein binding and stereoselectivity of nonsteroidal anti-inflammatory drugs.

Authors:  F Lapicque; N Muller; E Payan; N Dubois; P Netter
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of dexketoprofen.

Authors:  M J Barbanoj; R M Antonijoan; I Gich
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Stereoselective binding of mexiletine and ketoprofen enantiomers with human serum albumin domains.

Authors:  Da Shi; Yin-xiu Jin; Yi-hong Tang; Hai-hong Hu; Si-yun Xu; Lu-shan Yu; Hui-di Jiang; Su Zeng
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

6.  The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis.

Authors:  P J Hayball; R L Nation; F Bochner; L N Sansom; M J Ahern; M D Smith
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

7.  A multicentre, randomised, double-blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.

Authors:  H Zippel; A Wagenitz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.